ReviewCurrent urology reports2018
Role of Angio-Embolization for Renal Cell Carcinoma.
Review in Current urology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- Expanding the Scope of Interventional Oncology: Locoregional Therapies in Extrahepatic Malignancies.Cancers · 2025Review
- Management conundrum in a case of renal cell cancer (RCC) on dual antiplatelet therapy (DAPT) for recently placed coronary drug-eluting stent (DES).BMJ case reports · 2024Article
- Early-Stage Renal Cell Carcinoma Locoregional Therapies: Current Approaches and Future Directions.Clinical Medicine Insights. Oncology · 2024Review
- Spontaneous renal tumour regression following an aortic dissection.Annals of the Royal College of Surgeons of England · 2024Article
- Introduction to interventional oncology: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.Pediatric blood & cancer · 2023Article
- Endovascular management of RCC in one-kidney patient: a case report study.Annals of medicine and surgery (2012) · 2023Article
- Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study.BMC cancer · 2023Article
- Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors.Molecular therapy oncolytics · 2022Review
- Selective Arterial Embolization with N-Butyl Cyanoacrylate Prior to CT-Guided Percutaneous Cryoablation of Kidney Malignancies: A Single-Center Experience.Journal of clinical medicine · 2021Article
- Immediate preoperative renal artery embolization in the resection of complex renal tumors (UroCCR-48 Reinbol study).International urology and nephrology · 2021Article
- Update on Transradial Access for Percutaneous Transcatheter Visceral Artery Embolization.Korean journal of radiology · 2021Review
- Surgical Tips for Inferior Vena Cava Thrombectomy.Current urology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo provide the technical aspects of, clinical indications for, status of the current literature on, and emerging concepts in trans-arterial embolization (TAE) for renal cell carcinoma. RECENT
findingsTAE has been evaluated in several retrospective series as a neoadjuvant therapy prior to surgical resection of RCC to reduce tumor vascularity and minimize intra-operative blood loss. TAE has also been examined retrospectively as a neoadjuvant therapy prior to the percutaneous ablation of RCC to reduce blood loss and procedural complications. TAE can potentially palliate symptoms of RCC such as pain and hematuria. Trans-arterial chemoembolization and trans-arterial radioembolization are emerging concepts for RCC. Although there have been no prospective, randomized trials demonstrating improved clinical or oncologic outcomes from TAE for patients with RCC, several retrospective studies have shown encouraging results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.